August 2016

Fidia Pharma’s gel gives lasting OA pain relief

Parsippany, NJ-based Fidia Pharma USA’s injectable viscoelastic gel significantly improves knee osteoarthritis (OA) pain for up to a year in patients younger than 40 years, according to data presented July 7 at the annual meeting of the American Orthopaedic Society for Sports Medicine (AOSSM) in Colorado Springs, CO.

Italian investigators presented data from a multicenter, open-label phase III study that involved giving 50 patients two intra-articular injections (3 mL) of Hymovis one week apart. Researchers assessed knee pain using several tools, including the OMERACT-OARSI (Outcome Mea­sures in Rheumatology-Osteo­arthritis Research Society International) responder criteria, at the beginning of the study, immediately after the injections, and at six months, and conducted a year of follow-up assessment.

All measures showed significant improvement from baseline that was maintained for 52 weeks, and 88% of patients improved enough to be classified as responders by OMERACT-OARSI criteria.

The European Review for Medical and Pharmacological Sciences first published the results in March.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.